Who is affected by this change?

This affects Independence Blue Cross Oncology, Hematology providers on Medicare Advantage plans.

When does this change take effect?

This change is effective Apr 20, 2026.

Back to dashboard

Medicare AdvantageCoverageMedium impact

MA08.192, Belantamab mafodotin-blmf (Blenrep)

Independence Blue Cross·Oncology, Hematology·Pharmacy

Effective date

Apr 20, 2026

We identified it

Jun 19, 2026

Days to comply

—

Summary

A new Medicare Advantage policy MA08.192 has been established for Belantamab mafodotin-blmf (Blenrep), a specialty oncology medication. This policy will govern coverage and billing requirements for this drug starting April 20, 2026.

Action Required

Action needed

Before April 20, 2026: Billing team must review the full policy details at the provided URL to understand coverage criteria, prior authorization requirements, and billing procedures for Belantamab mafodotin-blmf (Blenrep). Update billing system with appropriate HCPCS codes and coverage rules once complete policy is available.

Related policy hubs

Independence Blue Cross policies Oncology Hematology